ONESOURCE Specialty Pharma Secures VAI Classification from USFDA for Bangalore Facility 4 days ago
ONESOURCE Specialty Pharma has received a 'Voluntary Action Indicated' (VAI) classification from the U.S. Food and Drug Administration for its manufacturing facility in Bangalore, India. This classification indicates that while minor issues were observed, they do not require regulatory action. The VAI status validates the company's compliance with regulatory standards and allows continued operations without significant hurdles. It positions ONESOURCE favorably in the pharmaceutical industry, especially for the U.S. market, while also indicating areas for minor improvements.
OneSource Specialty Pharma's Unit 2 Secures ANVISA GMP Certification, Expanding Market Reach to Brazil Apr 10, 2025
SEBI Guidance Halts OneSource Specialty Pharma's QIP Plans Post-Listing Mar 07, 2025